TNF Pharmaceuticals, Inc.
TNFA
$0.22
$0.02814.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.06M | 1.12M | 1.46M | 1.59M | 1.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.19M | 1.83M | 1.86M | 2.78M | 4.91M |
| Operating Income | -2.19M | -1.83M | -1.86M | -2.78M | -4.91M |
| Income Before Tax | -2.06M | -1.93M | -9.57M | -9.80M | -2.36M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.06M | -1.93M | -9.57M | -9.80M | -2.36M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.06M | -1.93M | -9.57M | -9.80M | -2.36M |
| EBIT | -2.19M | -1.83M | -1.86M | -2.78M | -4.91M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.09 | -1.11 | -4.55 | -5.14 | -2.72 |
| Normalized Basic EPS | -0.45 | -0.53 | -2.63 | -2.86 | -0.82 |
| EPS Diluted | -1.09 | -1.11 | -4.55 | -5.14 | -2.72 |
| Normalized Diluted EPS | -0.45 | -0.53 | -2.63 | -2.86 | -0.82 |
| Average Basic Shares Outstanding | 2.88M | 2.42M | 2.28M | 2.14M | 1.80M |
| Average Diluted Shares Outstanding | 2.88M | 2.42M | 2.28M | 2.14M | 1.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -65.72% | -- | 0.00% | -11.57% | -61.44% |